| Year |
Citation |
Score |
| 2019 |
Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers CG, Chen WP, Carmichael JC, Chung J, Richmond E, Rodriguez LM, Szabo E, Ford LG, Pollak MN, Meyskens FL. A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. Cancer Prevention Research (Philadelphia, Pa.). PMID 31818851 DOI: 10.1158/1940-6207.Capr-18-0262 |
0.35 |
|
| 2018 |
Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM. Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. Biological Chemistry. PMID 30352021 DOI: 10.1515/Hsz-2018-0327 |
0.338 |
|
| 2018 |
Moore H, Unger J, Phillips K, Boyle F, Hitre E, Moseley A, Porter D, Francis P, Goldstein L, Gomez H, Vallejos C, Partridge A, Dakhil S, Garcia A, Gralow J, ... ... Meyskens F, et al. Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-15-01 |
0.308 |
|
| 2018 |
Liu-Smith F, Wang Z, Meyskens F. ROS-independent inhibition of melanoma tumor growth by luteolin involves BRAF and the MAPK pathway Free Radical Biology and Medicine. 128. DOI: 10.1016/J.Freeradbiomed.2018.10.148 |
0.325 |
|
| 2017 |
Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL, Andresen BT, Huang Y. Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. Cancer Prevention Research (Philadelphia, Pa.). PMID 28912118 DOI: 10.1158/1940-6207.Capr-17-0132 |
0.317 |
|
| 2017 |
Liu-Smith F, Wang Z, Guo KL, Farhat A, Liu J, Meyskens FL. Double Discordance in the ROS-induction and Anti-tumor activity of Luteolin, a Classical Free Radical Scavenger Free Radical Biology and Medicine. 112: 93. DOI: 10.1016/J.Freeradbiomed.2017.10.137 |
0.346 |
|
| 2016 |
Meyskens FL. What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. Journal of the National Cancer Institute. 108. PMID 27986883 DOI: 10.1093/Jnci/Djw252 |
0.389 |
|
| 2016 |
Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. Trials. 17: 400. PMID 27519183 DOI: 10.1186/S13063-016-1524-9 |
0.358 |
|
| 2016 |
Uchio E, Meyskens FL, Wang PH. Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity. Cancer Prevention Research (Philadelphia, Pa.). PMID 27432345 DOI: 10.1158/1940-6207.Capr-16-0173 |
0.333 |
|
| 2016 |
Liu-Smith F, Meyskens FL. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. Molecular Nutrition & Food Research. 60: 1264-74. PMID 26865001 DOI: 10.1002/Mnfr.201500822 |
0.335 |
|
| 2016 |
Meyskens FL. Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals. Cancer Prevention Research (Philadelphia, Pa.). 9: 11-2. PMID 26701663 DOI: 10.1158/1940-6207.Capr-15-0401 |
0.324 |
|
| 2016 |
Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. Journal of the National Cancer Institute. 108. PMID 26547931 DOI: 10.1093/Jnci/Djv309 |
0.356 |
|
| 2016 |
Albain KS, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell D, Einspahr DE, Anderson GL, Hershman DL, Goodman GE, Brown P, Meyskens FL, et al. Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Journal of Clinical Oncology. 34: 547-547. DOI: 10.1200/Jco.2016.34.15_Suppl.547 |
0.349 |
|
| 2016 |
Liu F, Panchal PP, Wang Z, Farhat A, Garcia A, Fagundes T, Filipp F, Meyskens FL. Abstract 2399: System analysis of adapted and quiescent/dormancy(QD) models of drug resistance in melanoma cell lines Cancer Research. 76: 2399-2399. DOI: 10.1158/1538-7445.Am2016-2399 |
0.323 |
|
| 2016 |
Liu-Smith F, Meyskens FL, Philip F. System Analysis of the Molecular Characteristics of the Adapted and Quiescent/Dormancy(QD) State in an in Vitro Model for Late Relapse of Metastatic Melanoma Free Radical Biology and Medicine. 100. DOI: 10.1016/J.Freeradbiomed.2016.10.330 |
0.332 |
|
| 2015 |
Fabian CJ, Meyskens FL, Bajorin DF, George TJ, Jeter JM, Khan S, Tyne CA, William WN. Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527778 DOI: 10.1200/Jco.2015.63.5979 |
0.306 |
|
| 2015 |
Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL, Wade JL, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. Journal of Acupuncture and Meridian Studies. 8: 152-8. PMID 26100070 DOI: 10.1016/J.Jams.2015.03.006 |
0.321 |
|
| 2015 |
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, et al. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prevention Research (Philadelphia, Pa.). 8: 222-30. PMID 25604134 DOI: 10.1158/1940-6207.Capr-14-0148 |
0.343 |
|
| 2015 |
Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 47-57. PMID 25096604 DOI: 10.1093/Annonc/Mdu225 |
0.327 |
|
| 2015 |
Liu-Smith F, Farhat A, Arce A, Taylor TH, Ziogas A, Wang Z, Yourk V, Liu J, McEligot A, Anton-Culver H, Meyskens FL. Gender difference in the association of melanoma etiology to solar UV exposure. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20012 |
0.316 |
|
| 2015 |
Zell JA, McLaren CE, Morgan TR, Lawson MJ, Rezk S, Albers GC, Chen W, Carmichael JC, Rodriguez L, Szabo E, Ford L, Pollak M, Meyskens FL. Abstract A21: A Phase IIa trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A21 |
0.382 |
|
| 2014 |
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, ... Meyskens FL, et al. Prevention and early detection of prostate cancer. The Lancet. Oncology. 15: e484-92. PMID 25281467 DOI: 10.1016/S1470-2045(14)70211-6 |
0.307 |
|
| 2014 |
Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, ... ... Meyskens FL, et al. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1638-48. PMID 25028457 DOI: 10.1158/1055-9965.Epi-14-0202 |
0.345 |
|
| 2014 |
Dellinger RW, Liu-Smith F, Meyskens FL. Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. Journal of Photochemistry and Photobiology. B, Biology. 138: 317-23. PMID 25022944 DOI: 10.1016/J.Jphotobiol.2014.06.006 |
0.343 |
|
| 2014 |
Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research (Philadelphia, Pa.). 7: 886-95. PMID 24961880 DOI: 10.1158/1940-6207.Capr-14-0058 |
0.322 |
|
| 2014 |
Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1494-504. PMID 24732629 DOI: 10.1158/1055-9965.Epi-14-0115 |
0.319 |
|
| 2014 |
Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prevention Research (Philadelphia, Pa.). 7: 496-504. PMID 24614012 DOI: 10.1158/1940-6207.Capr-13-0189 |
0.338 |
|
| 2014 |
Meyskens FL, Simoneau AR, Gerner EW. Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 202: 115-20. PMID 24531785 DOI: 10.1007/978-3-642-45195-9_14 |
0.345 |
|
| 2014 |
Henry NL, Unger JM, Schott A, Hansen L, Lew D, Wade JL, Moinpour C, Hortobagyi GN, Meyskens FL. A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps9662 |
0.328 |
|
| 2013 |
Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute. 105: 1132-41. PMID 23843441 DOI: 10.1093/Jnci/Djt174 |
0.324 |
|
| 2013 |
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2627-33. PMID 23733756 DOI: 10.1200/Jco.2012.44.8738 |
0.34 |
|
| 2013 |
Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.). 6: 410-8. PMID 23639862 DOI: 10.1158/1940-6207.Capr-13-0004 |
0.37 |
|
| 2013 |
Xie L, Meyskens FL. The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines. Melanoma Research. 23: 102-13. PMID 23344158 DOI: 10.1097/Cmr.0B013E32835Df5E4 |
0.341 |
|
| 2013 |
Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. British Journal of Cancer. 108: 512-8. PMID 23340449 DOI: 10.1038/Bjc.2013.15 |
0.328 |
|
| 2013 |
Yang Z, Misner B, Ji H, Poulos TL, Silverman RB, Meyskens FL, Yang S. Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma Antioxidants and Redox Signaling. 19: 433-447. PMID 23199242 DOI: 10.1089/Ars.2012.4563 |
0.349 |
|
| 2013 |
Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, Klein EA, Cook ED, Darke AK, Arnold KB, Anderson K, Yee M, Meyskens FL, Baker LH. Moving a randomized clinical trial into an observational cohort. Clinical Trials (London, England). 10: 131-42. PMID 23064404 DOI: 10.1177/1740774512460345 |
0.368 |
|
| 2013 |
Lipkin S, Bhattacharya A, Morgan T, Zell J, Gillen D, Wong V, Chung J, Chen WP, Gonzalez R, Meyskens F, Rodriguez L, Szabo E, Carroll R, Benya R. Abstract CN07-01: A phase IIa randomized, double-blind trial of erlotinib in inhibiting EGF receptor signaling in aberrant crypt foci of the colon Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Cn07-01 |
0.321 |
|
| 2012 |
Klein EA, Thompson I, Tangen CM, Lucia MS, Goodman P, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Parsons JK, Chin J, Darke AK, ... ... Meyskens FL, et al. Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 7. PMID 27968278 DOI: 10.1200/Jco.2012.30.5_Suppl.7 |
0.326 |
|
| 2012 |
Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. Plos One. 7: e47696. PMID 23110092 DOI: 10.1371/Journal.Pone.0047696 |
0.359 |
|
| 2012 |
Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes & Control : Ccc. 23: 1739-44. PMID 22907422 DOI: 10.1007/S10552-012-0051-6 |
0.303 |
|
| 2012 |
Braithwaite D, Boffetta P, Rebbeck TR, Meyskens F. Cancer prevention for global health: a report from the ASPO International Cancer Prevention Interest Group. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1606-10. PMID 22850804 DOI: 10.1158/1055-9965.Epi-12-0848 |
0.342 |
|
| 2012 |
Hershman DL, Unger JM, Crew KD, Moinpour C, Minasian LM, Hansen L, Lew D, OKane P, Wade JL, Wong S, Hortobagyi GN, Meyskens FL, Albain KS. SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. Journal of Clinical Oncology. 30: 9018-9018. DOI: 10.1200/Jco.2012.30.15_Suppl.9018 |
0.306 |
|
| 2012 |
Baker LH, Crowley JJ, Valdivieso M, Dominguez RL, Bravo LE, Pena R, Meza-Montenegro MM, Correa P, Chey WD, Morgan DR, Meyskens FL, Goodman GE. Abstract SY26-02: SWOG S0701 phase III randomized trial of three antibiotic regimens to eradicate helicobacter pylori: efficacy and failure at one year Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy26-02 |
0.366 |
|
| 2012 |
Xie L, Meyskens F. Abstract 2823: PHA-739358, a pan-Aurora kinase inhibitor, induces apoptosis and inhibits invasion in melanoma cell lines Cancer Research. 72: 2823-2823. DOI: 10.1158/1538-7445.Am2012-2823 |
0.402 |
|
| 2012 |
Dellinger RW, Ahmed AS, Duong PH, Meyskens FL. Abstract 268: Regulation of the UDP-glucuronosyltransferases (UGTs) by UV exposure in human melanocytes Cancer Research. 72: 268-268. DOI: 10.1158/1538-7445.Am2012-268 |
0.346 |
|
| 2012 |
Liu F, Garcia A, Meyskens F. Abstract 2418: NADPH Oxidase 1 over-expression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells Cancer Research. 72: 2418-2418. DOI: 10.1158/1538-7445.Am2012-2418 |
0.314 |
|
| 2012 |
Yang S, Zheng Z, Misner B, Chamberlin R, Meyskens FL. Abstract 1937: APE/Ref-1, a drugable target for the therapy of human melanoma Cancer Research. 72: 1937-1937. DOI: 10.1158/1538-7445.Am2012-1937 |
0.341 |
|
| 2011 |
Lin BS, Zell JA, Madson N, McLaren CE, Gerner EW, Meyskens FL. Role of obesity in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 374. PMID 27985542 DOI: 10.1200/Jco.2011.29.4_Suppl.374 |
0.303 |
|
| 2011 |
Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, ... ... Meyskens FL, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 306: 1549-56. PMID 21990298 DOI: 10.1001/Jama.2011.1437 |
0.332 |
|
| 2011 |
Chu DZ, Hussey MA, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clinical Colorectal Cancer. 10: 310-6. PMID 21782524 DOI: 10.1016/J.Clcc.2011.06.005 |
0.337 |
|
| 2011 |
Meyskens FL. Therapeutic prevention of colorectal carcinogenesis. Journal of Carcinogenesis. 10: 13. PMID 21712960 DOI: 10.4103/1477-3163.79682 |
0.403 |
|
| 2011 |
Meyskens FL, Gerner EW. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach. Cancer Prevention Research (Philadelphia, Pa.). 4: 628-32. PMID 21543341 DOI: 10.1158/1940-6207.Capr-11-0162 |
0.303 |
|
| 2011 |
Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, Goodison S, Carpenter P, Wang-Rodriguez J, Simoneau A, Meyskens F, et al. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Research. 71: 2476-87. PMID 21459804 DOI: 10.1158/0008-5472.Can-10-2585 |
0.304 |
|
| 2011 |
Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prevention Research (Philadelphia, Pa.). 4: 354-64. PMID 21372035 DOI: 10.1158/1940-6207.Capr-10-0098 |
0.34 |
|
| 2011 |
Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prevention Research (Philadelphia, Pa.). 4: 311-23. PMID 21372031 DOI: 10.1158/1940-6207.Capr-09-0014 |
0.335 |
|
| 2011 |
Zell JA, McLaren CE, Albers CG, Gerner EW, Wenzel LB, Meyskens FL. A phase IIa clinical biomarker trial of aspirin and dietary arginine restriction in colorectal cancer patients. Journal of Clinical Oncology. 29: TPS132-TPS132. DOI: 10.1200/Jco.2011.29.15_Suppl.Tps132 |
0.356 |
|
| 2011 |
Carpenter PM, Chen W, McLaren CE, Gerner EW, Meyskens FL. Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-Pr-01 |
0.339 |
|
| 2011 |
Taylor TH, Kennedy AR, Perloff M, Meyskens FL. Abstract B82: Two factors contribute to negative results of a phase-IIB chemoprevention trial of Bowman-Birk inhibitor concentrate on oral leukoplakia Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-B82 |
0.326 |
|
| 2011 |
Hershman D, Unger J, Crew K, Moinpour C, Minasian L, Hansen L, Lew D, Kaberle K, Wade J, Meyskens F. OT2-07-02: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-07-02 |
0.329 |
|
| 2011 |
Meyskens FL, Yang S, Yang Z, Ji H, Poulos Tl, Silverman RB. Neuronal Nitric Oxide Synthase (nNOS)/NO, An Accelerator of Melanoma Progression, is a Potential Target for Chemoprevention Free Radical Biology and Medicine. 51: S91-S92. DOI: 10.1016/J.Freeradbiomed.2011.10.416 |
0.303 |
|
| 2010 |
Meyskens FL, McLaren CE. Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? Journal of the National Cancer Institute. 102: 1815-7. PMID 21115881 DOI: 10.1093/Jnci/Djq466 |
0.326 |
|
| 2010 |
Liu F, Singh A, Yang Z, Garcia A, Kong Y, Meyskens FL. MiTF links Erk1/2 kinase and p21 CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells. Molecular Cancer. 9: 214. PMID 20701798 DOI: 10.1186/1476-4598-9-214 |
0.3 |
|
| 2010 |
Braithwaite D, Wernli KJ, Anton-Culver H, Engstrom P, Greenberg ER, Meyskens F. Opportunities for cancer epidemiology and control in low- and middle-income countries: a report from the american society for preventive oncology international cancer prevention interest group. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1665-7. PMID 20615883 DOI: 10.1158/1055-9965.Epi-10-0523 |
0.328 |
|
| 2010 |
Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL. Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas. Journal of Clinical Oncology. 28: 1523-1523. DOI: 10.1200/Jco.2010.28.15_Suppl.1523 |
0.329 |
|
| 2010 |
Meyskens FL, Taylor T, Armstrong W, Kong L, Gu M, Gonzalez R, Villa M, Wong V, Garcia A, Perloff M, Kennedy A, Wan S, Ware JH, Messadi D, Lorch J, et al. Abstract CN02-05: Phase IIb randomized clinical chemoprevention trial of a soybean-derived compound (Bowman-Birk inhibitor concentrate) for oral leukoplakia Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Cn02-05 |
0.359 |
|
| 2010 |
Dellinger RW, Matundan HH, West AL, Meyskens FL. Abstract A9: UDP-glucuronosyltransferase 2B7 (UGT2B7) inhibits melanoma invasiveness Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-A9 |
0.329 |
|
| 2010 |
Lipkin SM, Lee J, Imagawa D, Zell J, Wong V, Gonzalez R, Della'Zanna G, Richmond E, Rodriguez L, Meyskens F. Abstract A67: Phase IIA trial testing erlotinib as an intervention against intraductal papillary mucinous neoplasms Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-A67 |
0.353 |
|
| 2010 |
Thompson PA, Wertheim BC, Zell JA, LeFleur B, Chen W, McLaren CE, Meyskens FL, Gerner EW. Abstract A29: Rectal mucosal polyamine and PGE2 levels and risk of colorectal adenomas in a phase IIb/III trial of combination difluoromethylornithine (DFMO) plus sulindac Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A29 |
0.339 |
|
| 2010 |
Yang S, Yang Z, Meyskens FL. Abstract 5466: nNOS, a novel target for melanoma prevention and therapy Cancer Research. 70: 5466-5466. DOI: 10.1158/1538-7445.Am10-5466 |
0.39 |
|
| 2010 |
Carroll RE, Turgeon DK, Vareed S, Kakarala M, Tuck M, McLarin C, Benya RV, Meyskens F, Brenner DE. Abstract 2906: Curcumin reduces aberrant crypt foci (ACF) number but does not alter prostaglandin E2 (PGE2) or 5-hydroxyeicosanopentaneic acid (5-HETE) concentration in ACF or in normal human colorectal mucosa Cancer Research. 70: 2906-2906. DOI: 10.1158/1538-7445.Am10-2906 |
0.347 |
|
| 2010 |
Jia Z, Wang Y, McClelland M, Sawyers A, Yao H, Rahmatpanah F, Xia X, Xu Q, Koziol J, Carpenter P, Wang-Rodriquez J, Simoneau A, Meyskens F, Sutton M, Lernhardt W, et al. Abstract 2735: Diagnosis of prostate cancer without tumor cells using differentially expressed genes in the tumor microenvironment Cancer Research. 70: 2735-2735. DOI: 10.1158/1538-7445.Am10-2735 |
0.302 |
|
| 2010 |
Dellinger RW, Matundan HH, Meyskens FL. Abstract 2553: Characterization of the UDP-Glucuronosyltransferases in melanocytes and melanoma Cancer Research. 70: 2553-2553. DOI: 10.1158/1538-7445.Am10-2553 |
0.362 |
|
| 2010 |
Liu F, Hwe C, Chu R, Meyskens F. Abstract 2552: Loss of MiTF sensitizes melanoma cells to chemotherapy due in part to reduced LAMP1 accumulation Cancer Research. 70: 2552-2552. DOI: 10.1158/1538-7445.Am10-2552 |
0.339 |
|
| 2009 |
Rial NS, Meyskens FL, Gerner EW. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. Essays in Biochemistry. 46: 111-24. PMID 20095973 DOI: 10.1042/Bse0460008 |
0.394 |
|
| 2009 |
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet. Oncology. 10: 501-7. PMID 19410194 DOI: 10.1016/S1470-2045(09)70035-X |
0.389 |
|
| 2009 |
Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prevention Research (Philadelphia, Pa.). 2: 209-12. PMID 19258540 DOI: 10.1158/1940-6207.Capr-08-0203 |
0.311 |
|
| 2009 |
Gerner EW, Meyskens FL. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 758-61. PMID 19188144 DOI: 10.1158/1078-0432.Ccr-08-2235 |
0.358 |
|
| 2009 |
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, ... ... Meyskens FL, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 301: 39-51. PMID 19066370 DOI: 10.1001/Jama.2008.864 |
0.347 |
|
| 2009 |
Yang S, Meyskens FL. Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma. Antioxidants & Redox Signaling. 11: 639-50. PMID 18715151 DOI: 10.1089/Ars.2008.2226 |
0.314 |
|
| 2008 |
Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Molecular Cancer Therapeutics. 7: 3751-60. PMID 19074850 DOI: 10.1158/1535-7163.Mct-08-0562 |
0.312 |
|
| 2008 |
Goodman GE, Alberts DS, Meyskens FL. Retinol, vitamins, and cancer prevention: 25 years of learning and relearning. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5495-6. PMID 18981460 DOI: 10.1200/Jco.2008.19.0884 |
0.413 |
|
| 2008 |
Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prevention Research (Philadelphia, Pa.). 1: 32-8. PMID 18841250 DOI: 10.1158/1940-6207.Capr-08-0042 |
0.338 |
|
| 2008 |
Gidanian S, Mentelle M, Meyskens FL, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake--a basis for the pro-oxidant state of melanoma. Photochemistry and Photobiology. 84: 556-64. PMID 18331399 DOI: 10.1111/J.1751-1097.2008.00309.X |
0.308 |
|
| 2008 |
Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 292-9. PMID 18268112 DOI: 10.1158/1055-9965.Epi-07-0658 |
0.313 |
|
| 2008 |
Meyskens FL. Another negative chemoprevention trial: what can we learn? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2-3. PMID 18172244 DOI: 10.1158/1078-0432.Ccr-07-2215 |
0.3 |
|
| 2008 |
Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 66-75. PMID 18165642 DOI: 10.1200/Jco.2007.12.3604 |
0.304 |
|
| 2008 |
Zell JA, McLaren CE, Gerner EW, Meyskens FL. Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo Journal of Clinical Oncology. 26: 1502-1502. DOI: 10.1200/Jco.2008.26.15_Suppl.1502 |
0.304 |
|
| 2008 |
Meyskens F. Abstract ED08-01: How should we optimize technology to allow personalized medicine? Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Ed08-01 |
0.329 |
|
| 2008 |
Simon J, Meyskens F. Abstract B26: Analyzing health benefits beyond the treatment period Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-B26 |
0.344 |
|
| 2008 |
Yang Z, Yang S, Misner B, Chiu R, Meyskens F. Abstract A137: NO initiates progression of human melanoma via a feedback loop mediated by APE/Ref-1, new opportunities for chemoprevention. Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-A137 |
0.328 |
|
| 2008 |
Meyskens FL, Gerner EW, Pelot D, Carpenter PM, McLaren CE, Fujikawa-Brooks S, Lawson M, Kidao J, McCracken J, Albers G, Ahnen DJ, Turgeon K. Abstract LB-142: Marked efficacy of difluoromethylornithine plus sulindac in reducing recurrent colorectal adenomas in patients with prior adenomas: Results of a randomized, placebo-controlled, double-blind Phase III trial. Clinical Research. DOI: 10.1158/1538-7445.Am2008-Lb-142 |
0.317 |
|
| 2008 |
Pelot D, Meyskens FL, Gerner E, McLaren CE, Fujikawa-Brooks SE, Lawson MJ, Kidao J, McCracken J, Griffin R, Albers C, Carpenter P, Ahnen D, Turgeon D, Hagedorn CH. 804 Marked Efficacy of Difluoromethylornithine (DFMO) Plus Sulindac in Reducing Recurrent Colorectal Adenomas in Patients with Prior Adenomas: Results of a Randomized, Placebo-Controlled Double-Blind Trial Gastroenterology. 134: A-113-A-114. DOI: 10.1016/S0016-5085(08)60529-6 |
0.315 |
|
| 2007 |
Yang S, Misner BJ, Chiu RJ, Meyskens FL. Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. Carcinogenesis. 28: 2382-90. PMID 17566060 DOI: 10.1093/Carcin/Bgm128 |
0.304 |
|
| 2007 |
Gerner EW, Meyskens FL, Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids. 33: 189-95. PMID 17396214 DOI: 10.1007/S00726-007-0515-2 |
0.385 |
|
| 2007 |
Meyskens F. Cancer following total joint arthroplasty. Cancer Epidemiology, Biomarkers & Prevention. 16: 356-356. PMID 17301272 DOI: 10.1158/1055-9965.Epi-06-0793 |
0.316 |
|
| 2007 |
Fruehauf JP, Meyskens FL. Reactive oxygen species: a breath of life or death? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 789-94. PMID 17289868 DOI: 10.1158/1078-0432.Ccr-06-2082 |
0.353 |
|
| 2007 |
Ghajar CM, Suresh V, Peyton SR, Raub CB, Meyskens FL, George SC, Putnam AJ. A novel three-dimensional model to quantify metastatic melanoma invasion. Molecular Cancer Therapeutics. 6: 552-61. PMID 17267658 DOI: 10.1158/1535-7163.Mct-06-0593 |
0.325 |
|
| 2007 |
Elmore E, Jain A, Siddiqui S, Tohidian N, Meyskens FL, Steele VE, Redpath JL. Development and characteristics of a human cell assay for screening agents for melanoma prevention. Melanoma Research. 17: 42-50. PMID 17235241 DOI: 10.1097/Cmr.0B013E3280142F96 |
0.329 |
|
| 2007 |
Simoneau AR, Gerner EW, Ziogas A, Nagle R, Ahlering TE, Meyskens FL. 538: The Effect of Difluoromethylornithine on Prostate Size and Polyamines in Men at Familial Risk for Prostate Cancer: Results of a One Year, Randomized, Double Blind, Placebo Controlled Chemoprevention Trial Journal of Urology. 177: 179-179. DOI: 10.1016/S0022-5347(18)30778-X |
0.303 |
|
| 2006 |
Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, ... ... Meyskens FL, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3661-97. PMID 16778094 DOI: 10.1158/1078-0432.Ccr-06-1104 |
0.31 |
|
| 2006 |
Meyskens FL, Ransohoff DF. Predicting risk for the appearance of melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3522-3. PMID 16728487 DOI: 10.1200/Jco.2006.06.8163 |
0.36 |
|
| 2006 |
Goding C, Meyskens FL. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1069-73. PMID 16489058 DOI: 10.1158/1078-0432.Ccr-05-2648 |
0.362 |
|
| 2006 |
Mobasher M, Zell JA, Meyskens FL, Anton-Culver H. Race, socioeconomic status and survival difference in cutaneous melanoma patients in California. Journal of Clinical Oncology. 24: 8023-8023. DOI: 10.1200/Jco.2006.24.18_Suppl.8023 |
0.3 |
|
| 2005 |
Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Molecular Cancer Therapeutics. 4: 1923-35. PMID 16373707 DOI: 10.1158/1535-7163.Mct-05-0229 |
0.32 |
|
| 2005 |
Meyskens FL, Tully P. Principles of cancer prevention. Seminars in Oncology Nursing. 21: 229-35. PMID 16293510 DOI: 10.1016/J.Soncn.2005.06.002 |
0.337 |
|
| 2005 |
McEligot AJ, Yang S, Meyskens FL. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annual Review of Nutrition. 25: 261-95. PMID 16011468 DOI: 10.1146/Annurev.Nutr.25.050304.092633 |
0.304 |
|
| 2005 |
Meyskens FL, Hietanen P, Tannock IF. Talking to a patient. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4463-4. PMID 15994158 DOI: 10.1200/Jco.2005.04.002 |
0.31 |
|
| 2005 |
Meyskens FL, Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1366-9. PMID 15941942 DOI: 10.1158/1055-9965.Epi-04-0666 |
0.374 |
|
| 2005 |
Meyskens FL, Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner Recent Results in Cancer Research. 166: 113-124. PMID 15648187 DOI: 10.1007/3-540-26980-0_9 |
0.333 |
|
| 2005 |
Armstrong WB, Taylor TH, Meyskens FL. Can a marker be a surrogate for development of cancer, and would we know it if it exists? Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 166: 99-112. PMID 15648186 DOI: 10.1007/3-540-26980-0_8 |
0.348 |
|
| 2005 |
Yang S, Meyskens FL. Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Molecular Pharmacology. 67: 298-308. PMID 15492115 DOI: 10.1124/Mol.104.006023 |
0.303 |
|
| 2004 |
Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL, Omenn GS, Valanis B, Williams JH. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. Journal of the National Cancer Institute. 96: 1743-50. PMID 15572756 DOI: 10.1093/Jnci/Djh320 |
0.322 |
|
| 2004 |
Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nature Reviews. Cancer. 4: 781-92. PMID 15510159 DOI: 10.1038/Nrc1454 |
0.377 |
|
| 2004 |
Meyskens FL. Screening for cancer: valuable or not? Current Oncology Reports. 6: 485-90. PMID 15485619 DOI: 10.1007/S11912-004-0081-7 |
0.338 |
|
| 2004 |
McNulty SE, del Rosario R, Cen D, Meyskens FL, Yang S. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 17: 173-80. PMID 15016307 DOI: 10.1111/J.1600-0749.2004.00128.X |
0.324 |
|
| 2003 |
Meyskens FL. Management of human melanoma: what has the last decade wrought? The Oncologist. 8: 448-50. PMID 14530497 DOI: 10.1634/Theoncologist.8-5-448 |
0.388 |
|
| 2003 |
Chu DZJ, Chansky K, Alberts DS, Meyskens FL, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Goodman GE, Abbruzzese JL, Lippman SM. Adenoma recurrences after resection of colorectal carcinoma: Results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study Annals of Surgical Oncology. 10: 870-875. PMID 14527904 DOI: 10.1245/Aso.2003.03.037 |
0.328 |
|
| 2003 |
Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. The Laryngoscope. 113: 1687-702. PMID 14520092 DOI: 10.1097/00005537-200310000-00007 |
0.338 |
|
| 2003 |
Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, Meyskens FL. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 163. PMID 12903852 DOI: 10.1007/978-3-642-55647-0_15 |
0.378 |
|
| 2002 |
Follen M, Vlastos AT, Meyskens FL, Atkinson EN, Schottenfeld D. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes & Control : Ccc. 13: 855-73. PMID 12462551 DOI: 10.1023/A:1020660527600 |
0.333 |
|
| 2002 |
Meyskens FL. Chemoprevention of FAP with sulindac. Current Oncology Reports. 4: 463-4463. PMID 12385292 DOI: 10.1007/S11912-002-0061-8 |
0.331 |
|
| 2002 |
Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 125-33. PMID 11773161 DOI: 10.1200/Jco.20.1.125 |
0.309 |
|
| 2002 |
Linden K, Meyskens F. Session 7 S21. Chemoprevention of non-melanoma skin cancer: Experience with a polyphenol from green tea European Journal of Cancer. 38. DOI: 10.1016/S0959-8049(02)80629-3 |
0.319 |
|
| 2001 |
McNulty SE, Tohidian NB, Meyskens FL. RelA, p50 and Inhibitor of kappa B alpha are Elevated in Human Metastatic Melanoma Cells and Respond Aberrantly to Ultraviolet Light B Pigment Cell Research. 14: 456-465. PMID 11775058 DOI: 10.1034/J.1600-0749.2001.140606.X |
0.333 |
|
| 2001 |
Meyskens FL, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radical Biology & Medicine. 31: 799-808. PMID 11557318 DOI: 10.1016/S0891-5849(01)00650-5 |
0.3 |
|
| 2001 |
Follen M, Meyskens FL, Atkinson EN, Schottenfeld D. Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. Journal of the National Cancer Institute. 93: 1293-6. PMID 11535703 DOI: 10.1093/Jnci/93.17.1293 |
0.361 |
|
| 2001 |
Meyskens FL, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma Pigment Cell Research. 14: 148-154. PMID 11434561 DOI: 10.1034/J.1600-0749.2001.140303.X |
0.31 |
|
| 2001 |
Powell IJ, Meyskens FL. African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urology. 57: 178-181. PMID 11295621 DOI: 10.1016/S0090-4295(00)00968-7 |
0.307 |
|
| 2001 |
Klein EA, Meyskens FL. Potential target populations and clinical models for testing chemopreventive agents. Urology. 57: 171-173. PMID 11295619 DOI: 10.1016/S0090-4295(00)00966-3 |
0.346 |
|
| 2001 |
Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 57: 4-27. PMID 11295590 DOI: 10.1016/S0090-4295(00)00931-6 |
0.37 |
|
| 2001 |
Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. Journal of the National Cancer Institute. 93: 57-9. PMID 11136843 DOI: 10.1093/Jnci/93.1.57 |
0.317 |
|
| 2000 |
Meyskens FL. Chemoprevention of breast and colon cancer. Current Oncology Reports. 2: 223-224. PMID 11122846 DOI: 10.1007/S11912-000-0071-3 |
0.388 |
|
| 2000 |
Meyskens FL. Cancer prevention in the year 2025: an anticipation. European Journal of Cancer. 36: 1737-1740. PMID 10974620 DOI: 10.1016/S0959-8049(00)00166-0 |
0.314 |
|
| 2000 |
Moinpour CM, Sawyers Triplett J, McKnight B, Lovato LC, Upchurch C, Leichman CG, Muggia FM, Tanaka L, James WA, Lennard M, Meyskens FL. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psycho-Oncology. 9: 340-54. PMID 10960931 DOI: 10.1002/1099-1611(200007/08)9:4<340::Aid-Pon466>3.0.Co;2-F |
0.33 |
|
| 2000 |
Meyskens FL. Cancer population genetics and tumour prevention: an unfulfilled paradigm. European Journal of Cancer. 36: 1189-1192. PMID 10882855 DOI: 10.1016/S0959-8049(00)00083-6 |
0.347 |
|
| 2000 |
Armstrong WB, Meyskens FL. Chemoprevention of Head and Neck Cancer Otolaryngology-Head and Neck Surgery. 122: 728-735. PMID 10793355 DOI: 10.1016/S0194-5998(00)70205-1 |
0.332 |
|
| 2000 |
Meyskens FL. Criteria for implementation of large and multiagent clinical chemoprevention trials. Journal of Cellular Biochemistry. 77: 115-120. PMID 10762023 DOI: 10.1002/(Sici)1097-4644(2000)77:34+<115::Aid-Jcb18>3.0.Co;2-T |
0.355 |
|
| 2000 |
Meyskens F, Jungi W, Gerber M, Waard Fd, Heidemann E, Heim M, Joossens J, Salvini S, Trichopoulou A, Varela G, Wolfram G. WHO consensus conference on diet and cancer European Journal of Cancer Prevention. 9: 213-216. DOI: 10.1097/00008469-200006000-00009 |
0.336 |
|
| 1999 |
Meyskens FL. Chemoprevention of human cancer: a reasonable strategy? Recent Results in Cancer Research. 151: 113-121. PMID 10337722 DOI: 10.1007/978-3-642-59945-3_8 |
0.37 |
|
| 1999 |
Meyskens FL. Re: Cancer Chemoprevention: Progress and Promise Journal of the National Cancer Institute. 91: 563-565. PMID 10088631 DOI: 10.1093/Jnci/91.6.563 |
0.343 |
|
| 1999 |
Moinpour C, Savage M, Troxel A, Lovato L, Eisenberger M, Veith R, Higgins B, Skeel R, Yee M, Blumenstein B, Crawford E, Meyskens F. Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial Journal of Urology. 161: 1394-1395. DOI: 10.1016/S0022-5347(01)61702-6 |
0.312 |
|
| 1998 |
Meyskens FL. Principles of human chemoprevention. Hematology-Oncology Clinics of North America. 12: 935-941. PMID 9888014 DOI: 10.1016/S0889-8588(05)70034-4 |
0.369 |
|
| 1998 |
Moinpour CM, Savage MJ, Troxel A, Lovato LC, Eisenberger M, Veith RW, Higgins B, Skeel R, Yee M, Blumenstein BA, Crawford ED, Meyskens FL. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. Journal of the National Cancer Institute. 90: 1537-44. PMID 9790546 DOI: 10.1093/Jnci/90.20.1537 |
0.342 |
|
| 1998 |
Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. Journal of the National Cancer Institute. 90: 1212-8. PMID 9719082 DOI: 10.1093/Jnci/90.16.1212 |
0.369 |
|
| 1997 |
Meyskens FL, Chau HV, Tohidian N, Buckmeier J. Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. Pigment Cell Research. 10: 184-189. PMID 9266607 DOI: 10.1111/J.1600-0749.1997.Tb00482.X |
0.312 |
|
| 1997 |
Gordon W, Siegmund K, Stanisic TH, McKnight B, Harris IT, Carroll PR, Paradelo JC, Meyers FJ, Chapman RA, Meyskens FL. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. International Journal of Radiation Oncology, Biology, Physics. 38: 83-94. PMID 9212008 DOI: 10.1016/S0360-3016(97)00235-6 |
0.305 |
|
| 1996 |
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial Journal of the National Cancer Institute. 88: 1550-1559. PMID 8901853 DOI: 10.1093/Jnci/88.21.1550 |
0.362 |
|
| 1996 |
Atwood JR, Giordano L, Vargas P, Blackwell GG, Earnest DL, Meyskens F, Alberts DS. Adherence enhancers in pill-related clinical trials: A health behavior in cancer prevention model-based approach Patient Education and Counseling. 28: 15-23. PMID 8852203 DOI: 10.1016/0738-3991(96)00858-0 |
0.325 |
|
| 1996 |
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects Of A Combination Of Beta Carotene And Vitamin A On Lung Cancer And Cardiovascular Disease The New England Journal of Medicine. 334: 1150-1155. PMID 8602180 DOI: 10.1056/Nejm199605023341802 |
0.342 |
|
| 1995 |
Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leukemia Research. 19: 605-12. PMID 7564470 DOI: 10.1016/0145-2126(95)00032-J |
0.327 |
|
| 1995 |
Meyskens FL, Manetta A. Prevention of cervical intraepithelial neoplasia and cervical cancer The American Journal of Clinical Nutrition. 62: 1417-1419. PMID 7495240 DOI: 10.1093/Ajcn/62.6.1417S |
0.332 |
|
| 1995 |
Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. Journal of the National Cancer Institute. 87: 1710-3. PMID 7473820 DOI: 10.1093/Jnci/87.22.1710 |
0.363 |
|
| 1994 |
Yamanishi DT, Meyskens FL. Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Critical Reviews in Oncogenesis. 5: 429-450. PMID 8519807 DOI: 10.1615/Critrevoncog.V5.I5.10 |
0.352 |
|
| 1994 |
Meyskens FL, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. Journal of the National Cancer Institute. 86: 539-43. PMID 8133537 DOI: 10.1093/Jnci/86.7.539 |
0.32 |
|
| 1994 |
Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps Journal of the National Cancer Institute. 86: 1122-1130. PMID 8028034 DOI: 10.1093/Jnci/86.15.1122 |
0.363 |
|
| 1994 |
Meyskens FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2060-5. PMID 7931474 DOI: 10.1200/Jco.1994.12.10.2060 |
0.337 |
|
| 1993 |
Meyskens FL. Retinoids as anticancer agents. Journal of Clinical Oncology. 11: 588-589. PMID 8445437 DOI: 10.1200/Jco.1993.11.3.588 |
0.319 |
|
| 1993 |
Thornquist MD, Omenn GS, Goodman GE, Grizzle JE, Rosenstock L, Barnhart S, Anderson GL, Hammar S, Balmes J, Cherniack M, Cone J, Cullen MR, Glass A, Keogh JP, Meyskens F, et al. Statistical design and monitoring of the carotene and retinol efficacy trial (CARET) Controlled Clinical Trials. 14: 308-324. PMID 8365195 DOI: 10.1016/0197-2456(93)90228-6 |
0.326 |
|
| 1993 |
Garewal H, Meyskens F, Friedman S, Alberts D, Ramsey L. Oral cancer prevention: the case for carotenoids and anti-oxidant nutrients. Preventive Medicine. 22: 701-711. PMID 8234210 DOI: 10.1006/Pmed.1993.1064 |
0.399 |
|
| 1993 |
Powell MB, Rosenberg RK, Graham MJ, Birch ML, Yamanishi DT, Buckmeier JA, Meyskens FL. Protein kinase C β expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate Journal of Cancer Research and Clinical Oncology. 119: 199-206. PMID 7678596 DOI: 10.1007/Bf01624431 |
0.3 |
|
| 1992 |
Meyskens FL. Isn't skin cancer preventable? Journal of the National Cancer Institute. 84: 286-287. PMID 1738176 DOI: 10.1093/Jnci/84.5.286 |
0.407 |
|
| 1992 |
Verdi CJ, Taylor CW, Croghan MK, Dalke P, Meyskens FL, Hersh EM. Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer. Journal of Immunotherapy. 11: 286-291. PMID 1599914 DOI: 10.1097/00002371-199205000-00007 |
0.345 |
|
| 1992 |
Lippman SM, Bassford TL, Meyskens FL. A quantitatively scored cancer-risk assessment tool: its development and use. Journal of Cancer Education. 7: 15-36. PMID 1571244 DOI: 10.1080/08858199209528139 |
0.321 |
|
| 1992 |
Atwood JR, Aickin M, Giordano L, Benedict J, Bell M, Ritenbaugh C, Rees-McGee S, Sheehan E, Buller M, Ho E, Meyskens FL, Alberts D. The effectiveness of adherence intervention in a colon cancer prevention field trial Preventive Medicine. 21: 637-653. PMID 1332022 DOI: 10.1016/0091-7435(92)90071-O |
0.306 |
|
| 1991 |
Loescher LJ, Meyskens FL. Chemoprevention of human skin cancers. Seminars in Oncology Nursing. 7: 45-52. PMID 2011658 DOI: 10.1016/0749-2081(91)90054-S |
0.373 |
|
| 1991 |
Yamanishi DT, Graham M, Buckmeier JA, Meyskens FL. The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis. 12: 105-109. PMID 1988168 DOI: 10.1093/Carcin/12.1.105 |
0.302 |
|
| 1991 |
Garewal HS, Meyskens FL. Chemoprevention of cancer. Hematology-Oncology Clinics of North America. 5: 69-77. DOI: 10.1016/S0889-8588(18)30454-4 |
0.396 |
|
| 1991 |
Atwood JR, Buller MK, Sheehan ET, Benedict JA, Giordano L, Alberts DS, Earnest D, Meyskens FL. Acceptability, satisfaction and cost of a model-based newsletter for elders in a cancer prevention adherence promotion strategy Patient Education and Counseling. 18: 211-221. DOI: 10.1016/0738-3991(91)90130-W |
0.31 |
|
| 1990 |
Garewal HS, Meyskens FL, Killen D, Reeves D, Kiersch TA, Elletson H, Strosberg A, King D, Steinbronn K. Response of oral leukoplakia to beta-carotene. Journal of Clinical Oncology. 8: 1715-1720. PMID 2213107 DOI: 10.1200/Jco.1990.8.10.1715 |
0.313 |
|
| 1990 |
Alberts DS, Einspahr J, Rees-McGee S, Ramanujam P, Buller MK, Clark L, Ritenbaugh C, Atwood J, Pethigal P, Earnest D, Villar H, Phelps J, Lipkin M, Wargovich MJ, Meyskens FL. Effects of dietary wheat bran fiber on rectal epithelial cell proliferation in patients with resection for colorectal cancers. Journal of the National Cancer Institute. 82: 1280-1285. PMID 2165179 DOI: 10.1093/Jnci/82.15.1280 |
0.36 |
|
| 1990 |
Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Investigational New Drugs. 8: 317-9. PMID 2148744 DOI: 10.1007/Bf00171846 |
0.37 |
|
| 1990 |
Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL. Ocular toxic effects of fenretinide. Journal of the National Cancer Institute. 82: 1063. PMID 2140863 DOI: 10.1093/Jnci/82.12.1063 |
0.381 |
|
| 1990 |
Harari PM, Fuller DJ, Carper SW, Croghan MK, Meyskens FL, Shimm DS, Gerner EW. Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. International Journal of Radiation Oncology, Biology, Physics. 19: 89-96. PMID 2116388 DOI: 10.1016/0360-3016(90)90139-B |
0.347 |
|
| 1990 |
Garewal H, Meyskens FL. Beta-carotene didn't prevent cancer: what's up doc? Journal of the National Cancer Institute. 82: 1851-1853. PMID 2078244 DOI: 10.1093/Jnci/82.23.1851-A |
0.364 |
|
| 1989 |
Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi Journal of the American Academy of Dermatology. 20: 257-260. PMID 2915061 DOI: 10.1016/S0190-9622(89)70031-1 |
0.342 |
|
| 1989 |
Meyskens FL, Thomson SP, Buckmeier J. Replating efficiency of metastatic melanoma cells from lymph node and subcutaneous sites does not predict patient survival Clinical & Experimental Metastasis. 7: 627-632. PMID 2776367 DOI: 10.1007/Bf01753673 |
0.301 |
|
| 1989 |
Yohem KH, Seftor EA, Meyskens FL, Hendrix MJC. Cloning Efficiency Of Human-Melanoma Cells Is Modulated After Invasion Through A Reconstituted Basement-Membrane Cancer Letters. 45: 135-143. PMID 2731157 DOI: 10.1016/0304-3835(89)90148-1 |
0.3 |
|
| 1989 |
Lippman SM, Garewal HS, Meyskens FL. Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck Preventive Medicine. 18: 740-748. PMID 2694167 DOI: 10.1016/0091-7435(89)90045-5 |
0.368 |
|
| 1989 |
Welch-McCaffrey D, Hoffman B, Leigh SA, Loescher LJ, Meyskens FL. Surviving adult cancers. Part 2: Psychosocial implications Annals of Internal Medicine. 111: 517-524. PMID 2672926 DOI: 10.7326/0003-4819-111-6-517 |
0.313 |
|
| 1989 |
Loescher LJ, Welch-McCaffrey D, Leigh SA, Hoffman B, Meyskens FL. Surviving adult cancers. Part 1: Physiologic effects Annals of Internal Medicine. 111: 411-432. PMID 2669594 DOI: 10.7326/0003-4819-111-5-411 |
0.331 |
|
| 1989 |
Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Crowley J. Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations Journal of the National Cancer Institute. 81: 485-495. PMID 2646455 DOI: 10.1093/Jnci/81.7.485 |
0.31 |
|
| 1989 |
Harari PM, Fuller DJ, Carper SW, Croghan MK, Meyskens FL, Shimm DS, Gerner EW. Rationale for and initial clinical application of polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy International Journal of Radiation Oncology*Biology*Physics. 17: 113. DOI: 10.1016/0360-3016(89)90630-5 |
0.307 |
|
| 1989 |
Meyskens FL, Moon TE. Conference - Prevention Of Human Cancer - Introduction Preventive Medicine. 18: 551-552. DOI: 10.1016/0091-7435(89)90028-5 |
0.344 |
|
| 1988 |
Meyskens FL, Berdeaux DH, Parks B, Tong T, Loescher L, Moon TE. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer. 62: 1207-14. PMID 3409189 DOI: 10.1002/1097-0142(19880915)62:6<1207::Aid-Cncr2820620628>3.0.Co;2-A |
0.328 |
|
| 1988 |
Yohem KH, Slymen DJ, Bregman MD, Meyskens FL. Radiation survival of murine and human melanoma cells utilizing two assay systems: monolayer and soft agar. British Journal of Cancer. 57: 64-9. PMID 3348949 DOI: 10.1038/Bjc.1988.10 |
0.304 |
|
| 1988 |
Meyskens FL. Evolution of Cancer Prevention and Control Program at The Arizona Cancer Center Journal of the National Cancer Institute. 80: 1595-1598. PMID 3193477 DOI: 10.1093/Jnci/80.20.1595 |
0.316 |
|
| 1988 |
Meyskens FL. Thinking About Cancer Causality and Chemoprevention Journal of the National Cancer Institute. 80: 1278-1281. PMID 3172255 DOI: 10.1093/Jnci/80.16.1278 |
0.331 |
|
| 1988 |
Lippman SM, Meyskens FL. Vitamin A derivatives in the prevention and treatment of human cancer. Journal of the American College of Nutrition. 7: 269-284. PMID 3062055 DOI: 10.1080/07315724.1988.10720244 |
0.4 |
|
| 1988 |
BIRCH M, MEYSKENS F, KORC M. Protein Kinase C and Melanocyte Transformation Pigment Cell Research. 1: 163-168. DOI: 10.1111/J.1600-0749.1988.Tb00808.X |
0.318 |
|
| 1987 |
Yohem KH, Bregman MD, Meyskens FL. Effect of tumor colony definition on ionizing radiation survival curves of melanoma-colony forming cells. International Journal of Radiation Oncology, Biology, Physics. 13: 1725-33. PMID 3667379 DOI: 10.1016/0360-3016(87)90170-2 |
0.303 |
|
| 1987 |
Bregman MD, Buckmeier J, Funk C, Meyskens FL. Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 1: 124-8. PMID 3148916 DOI: 10.1111/J.1600-0749.1987.Tb00400.X |
0.323 |
|
| 1987 |
Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL. Isotretinoin and Cutaneous Helper T-Cell Lymphoma (Mycosis Fungoides) Archives of Dermatology. 123: 201-204. DOI: 10.1001/Archderm.1987.01660260071016 |
0.317 |
|
| 1986 |
Weiner SA, Surwit EA, Graham VE, Meyskens FL. A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Investigational New Drugs. 4: 241-244. PMID 3818228 DOI: 10.1007/Bf00179590 |
0.312 |
|
| 1986 |
Meyskens FL, Surwit ES. Clinical experience with topical tretinoin in the treatment of cervical dysplasia Journal of the American Academy of Dermatology. 15: 826-829. PMID 3534021 DOI: 10.1016/S0190-9622(86)70240-5 |
0.315 |
|
| 1986 |
Meyskens FL, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi Journal of the American Academy of Dermatology. 15: 822-825. PMID 3534020 DOI: 10.1016/S0190-9622(86)70239-9 |
0.356 |
|
| 1986 |
Meyskens FL, Kingsley EM, Glattke T, Loescher L, Booth A. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Investigational New Drugs. 4: 257-62. PMID 3102397 DOI: 10.1007/Bf00179593 |
0.346 |
|
| 1986 |
Bregman MD, Meyskens FL. Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid. International Journal of Cancer. Journal International Du Cancer. 37: 101-7. PMID 3079741 DOI: 10.1002/Ijc.2910370117 |
0.324 |
|
| 1985 |
Meyskens FL, Goodman GE, Alberts DS, Itri LM. 13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. Critical Reviews in Oncology Hematology. 3: 75-101. PMID 3893773 DOI: 10.1016/S1040-8428(85)80040-8 |
0.31 |
|
| 1984 |
Levine N, Miller RC, Meyskens FL. Oral isotretinoin therapy. Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. Archives of Dermatology. 120: 1215-1217. PMID 6591861 DOI: 10.1001/Archderm.120.9.1215 |
0.306 |
|
| 1984 |
Salmon SE, Meyskens FL, Alberts DS. Comparison of assays used for in vitro chemosensitivity testing of human tumours. British Journal of Cancer. 50: 725-726. PMID 6498072 DOI: 10.1038/Bjc.1984.243 |
0.35 |
|
| 1984 |
Thomson SP, Moon TE, Meyskens FL. Kinetics of clonogenic melanoma cell proliferation and the limits on growth within a bilayer agar system. Journal of Cellular Physiology. 121: 114-124. PMID 6480705 DOI: 10.1002/Jcp.1041210114 |
0.303 |
|
| 1984 |
Meyskens FL, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 1223-8. PMID 6387058 DOI: 10.1200/Jco.1984.2.11.1223 |
0.343 |
|
| 1983 |
Goodman GE, Alberts DS, Earnst DL, Meyskens FL. Phase I trial of retinol in cancer patients. Journal of Clinical Oncology. 1: 394-399. PMID 6668507 DOI: 10.1200/Jco.1983.1.6.394 |
0.32 |
|
| 1983 |
Persky B, Meyskens FL, Hendrix MJC. Diagnostic electron microscopy for amelanotic melanoma: Correlation of patient biopsy, soft agar assay, and xenograft Journal of Pathology. 141: 17-27. PMID 6620008 DOI: 10.1002/Path.1711410104 |
0.303 |
|
| 1983 |
Bregman MD, Meyskens FL. In vitro modulation of human and murine melanoma growth by prostanoid analogues. Prostaglandins. 26: 449-56. PMID 6581509 DOI: 10.1016/0090-6980(83)90179-X |
0.312 |
|
| 1983 |
Kummet T, Moon TE, Meyskens FL. Vitamin a: Evidence for its preventive role in human cancer∗ Nutrition and Cancer. 5: 96-106. PMID 6359074 DOI: 10.1080/01635588309513785 |
0.31 |
|
| 1983 |
Meyskens FL, Alberts DS, Salmon SE. Effect of 13‐cis‐retinoic acid and 4‐hydroxyphenyl‐all‐trans‐retinamide on human tumor colony formation in soft agar International Journal of Cancer. 32: 295-299. PMID 6224747 DOI: 10.1002/Ijc.2910320306 |
0.313 |
|
| 1983 |
Meyskens FL, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit EA. A Phase I Trial of β-all-trans-Retinoic Acid Delivered via a Collagen Sponge and a Cervical Cap for Mild or Moderate Intraepithelial Cervical Neoplasia Journal of the National Cancer Institute. 71: 921-925. DOI: 10.1093/Jnci/71.5.921 |
0.304 |
|
| 1983 |
Thomson SP, Wright MD, Meyskens FL. Improvement of human melanoma colony formation in soft agar using boiled instead of autodaved agar Stem Cells. 1: 85-91. DOI: 10.1002/Stem.5530010203 |
0.305 |
|
| 1982 |
Surwit EA, Graham V, Droegemueller W, Alberts D, Chvapil M, Dorr RT, Davis JR, Meyskens FL. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. American Journal of Obstetrics and Gynecology. 143: 821-3. PMID 7048932 DOI: 10.1016/0002-9378(82)90016-3 |
0.313 |
|
| 1982 |
Meyskens FL. Studies of retinoids in the prevention and treatment of cancer. Journal of the American Academy of Dermatology. 6: 824-827. PMID 6950958 DOI: 10.1016/S0190-9622(82)70072-6 |
0.353 |
|
| 1981 |
Meyskens FL, Moon TE, Dana B, Gilmartin E, Casey WJ, Chen HS, Franks DH, Young L, Salmon SE. Quantitation of drug sensitivity by human metastatic melanoma colony-forming units. British Journal of Cancer. 44: 787-97. PMID 7326191 DOI: 10.1038/Bjc.1981.277 |
0.346 |
|
| 1981 |
Moon TE, Salmon SE, White CS, Chen HG, Meyskens FL, Durie BGM, Alberts DS. Quantitative Association Between the in vitro Human Tumor Stem Cell Assay and Clinical Response to Cancer Chemotherapy Cancer Chemotherapy and Pharmacology. 6: 211-218. PMID 7318144 DOI: 10.1007/Bf00256973 |
0.315 |
|
| 1981 |
Meyskens FL. Modulation of abnormal growth by retinoids: A clinical perspective of the biological phenomenon Life Sciences. 28: 2323-2327. PMID 7019614 DOI: 10.1016/0024-3205(81)90495-1 |
0.32 |
|
| 1981 |
Alberts DS, Chen HS, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay Cancer Chemotherapy and Pharmacology. 6: 279-285. PMID 6172215 DOI: 10.1007/Bf00256981 |
0.368 |
|
| 1980 |
Salmon SE, Alberts DS, Durie BGM, Meyskens FL, Jones SE, Soehnlen B, Chen H-G, Moon T. Clinical correlations of drug sensitivity in the human tumor stem cell assay. Recent Results in Cancer Research. 74: 300-305. PMID 7444146 DOI: 10.1007/978-3-642-81488-4_36 |
0.306 |
|
| 1976 |
Neifeld JP, Meyskens F, Tormey DC, Javadpour N. The role of orchiectomy in the management of advanced male breast cancer Cancer. 37: 992-995. PMID 1253122 DOI: 10.1002/1097-0142(197602)37:2<992::Aid-Cncr2820370257>3.0.Co;2-B |
0.315 |
|
| Show low-probability matches. |